Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients
暂无分享，去创建一个
R. Houot | F. Jardin | T. Cluzeau | L. Ysebaert | E. Durot | N. Kamar | D. Boutboul | S. Choquet | J. Dantal | R. Trappe | L. Roulin | G. Venton | E. Bachy | V. Morel | L. Couzi | S. Caillard | H. Zimmermann | M. Moles-Moreau | Hugo Vargas González | L. Écotière | M. Baron | F. Suarez | D. Roos-Weil | C. Jacquet | Noureddine Balegroune | R. Guièze | E. Nicolas‐Virelizier | Pierre Walczak | Mohamed Touati | Michelle Elias | Kevin Ou
[1] Karen M. Chisholm,et al. Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric PTLD collaborative , 2022, British journal of haematology.
[2] R. Siebert,et al. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial , 2022, Leukemia.
[3] A. Rosenwald,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.
[4] T. Menne,et al. Front‐line management of post‐transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline , 2021, British journal of haematology.
[5] Scott E. Smith,et al. Burkitt Lymphoma International Prognostic Index. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Giné,et al. Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series , 2018, Annals of Hematology.
[7] W. Wilson,et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] G. Salles,et al. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Tousseyn,et al. How I treat posttransplant lymphoproliferative disorders. , 2015, Blood.
[10] D. Lenze,et al. Burkitt post‐transplantation lymphoma in adult solid organ transplant recipients , 2012, Cancer.
[11] G. Salles,et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. , 2012, The Lancet. Oncology.
[12] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Esteve,et al. Post-transplant Burkit t's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial) , 2003, Leukemia & lymphoma.
[14] A. Webster,et al. Post-transplant lymphoproliferative disorders , 2016, Nature Reviews Disease Primers.